Abstract: Compositions capable of reducing viability, inducing cell cycle arrest and/or reducing proliferation and/or migration of Glioblastoma multiforme (GMB) and ovarian cancer cells and methods of use thereof are provided. The compositions and uses thereof comprise phytocannabinoids.

Abstract: Compositions capable of reducing viability, initiating apoptosis, inducing cell cycle arrest and/or reducing migration of urothelial carcinoma cells and methods of use thereof are provided. The compositions and uses thereof comprise cannabinoids.

Abstract: A method of treating an inflammatory disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), wherein the fraction comprises cannabis derived active ingredients other than the THCA.

Abstract: A bio-ink comprising: (a) at least one polysaccharide; (b) at least one structural protein; and (c) fibrinogen, wherein the polysaccharide is selected from a group consisting of Sodium alginate Chitosan, Hyaluronic acid, Gellan gum, Dextran, Agarose, Poly(ethylene glycol), Pluronic and Carrageenan and the structural protein is selected from a group consisting of Gelatin, Collagen Vitronectin, Laminins and Fibronectin.

Abstract: Cannabinoidal compositions for the treatment of disease are provided. Accordingly, there is provided a method of treating a disease that can benefit from activating macrophages comprising administering to the subject a therapeutically effective amount of a composition comprising a cannabis derived fraction comprising phytocannabinoids, wherein said phytocannabinoids comprise at least 80% CBD and at least one of CBG and THCV. Also provided is a method of treating a cytokine storm comprising administering to the subject a therapeutically effective amount of a synthetic composition comprising phytocannabinoids, wherein said phytocannabinoids comprise at least 80% CBD and at least one of CBG and THCV.

Abstract: Described herein are a method of preparing a vegetable oil, comprising pressing a non-fruit tissue of a date palm offshoot, as well as a vegetable oil and a polysaccharide-containing fraction obtained by such a method. Further described herein is an oil comprising esters of fatty acids, wherein at least 10 weight percent of the fatty acids are linolelaidic acid, as well as compositions comprising a variety of ingredients, such as saccharides and amino acids, as characterized herein, and a method of isolating dihydrouracil from an oil and/or composition described herein. Further described is a method of preparing a vegetable oil, comprising pressing date kernel tissue.

Abstract: A method of treating a malignant disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a first liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), and a therapeutically effective amount of a second liquid chromatography fraction of a cannabis extract comprising at least 75% cannabigerolic acid (CBGA), wherein the first liquid chromatography fraction comprises cannabis derived active ingredients other than the THCA, and the second liquid chromatography fraction comprises cannabis derived active ingredients other than the CBGA, thereby treating the malignant disease in the subject.

Abstract: Compositions and methods for the treatment of cutaneous T cell lymphoma (CTCL) are provided. The compositions and uses thereof comprise cannabinoids.

Abstract: The present invention is directed to a composition consisting essentially of epigallocatechin, mannofuranose, ?-D-xylopyranose, gallic acid, palmitic acid, stearic acid, trans-catechin, cis-catechin, and an acceptable carrier, and a method of using same, such as for treating an inflammatory disease.

Abstract: Polar extracts of Erodium plants are disclosed as well as pharmaceutical compositions and cosmetic compositions comprising same. Uses of the polar extracts are also disclosed.

Abstract: A method of treating an inflammatory disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), wherein the fraction comprises cannabis derived active ingredients other than the THCA.

Abstract: A method of treating a malignant disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a first liquid chromatography fraction of a Cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), and a therapeutically effective amount of a second liquid chromatography fraction of a Cannabis extract comprising at least 75% cannabigerolic acid (CBGA), wherein the first liquid chromatography fraction comprises Cannabis derived active ingredients other than the THCA, and the second liquid chromatography fraction comprises Cannabis derived active ingredients other than the CBGA, thereby treating the malignant disease in the subject.

Abstract: A method of preparing an ex-vivo intestinal culture model is provided. The method comprising: (a) providing an intestinal tissue sample; (b) treating the intestinal tissue sample with a protease cleaving an extracellular matrix (ECM) component so as to break cell-cell contacts and obtain an intestinal preparation which maintains the overall intestinal tissue structure including villi and/or intestinal tissue layer orientation; (c) washing the preparation; and (d) culturing the preparation.

Abstract: Compound of formula X wherein P1 is a fused-ring system comprising one 6-membered and two 5-membered rings; v indicates an S or R configuration; or individual isomers or pharmaceutically acceptable salts thereof, or mixtures thereof, in the preparation of an active agent for preventing or inhibiting cell proliferation or for inducing cell death.

Abstract: A composition comprising at least one polymer, characterized by a surface energy having a value that ranges from 20 mJ/m2 to 60 mJ/m2, and an active agent (e.g., a plant hormone) is disclosed. A delivery device comprising the disclosed composition, adapted for installation on a part of a plant, is further disclosed. A method for applying a plant hormone to a plant is further disclosed.

Abstract: Polar extracts of Erodium plants are disclosed as well as pharmaceutical compositions and cosmetic compositions comprising same. Uses of the polar extracts are also disclosed.

Abstract: Compound of formula X wherein P1 is a fused-ring system comprising one 6-membered and two 5-membered rings; v indicates an S or R configuration; or individual isomers or pharmaceutically acceptable salts thereof, or mixtures thereof, in the preparation of an active agent for preventing or inhibiting cell proliferation or for inducing cell death.